Skip to main content
Seagen Logo
I am a ...
  • Patient or Caregiver
    • Overview
    • Diseases We Study
    • Real Stories
    • Clinical Trials
    • Support and Resources
  • Healthcare Professional
    • Overview
    • Medical Information
    • Clinical Data Requests
    • Investigator-Sponsored Trials
    • Medical Education Grants
  • I am a ...
  • Patient or Caregiver
  • Healthcare Professional
  • Who We Are
    • Mission and Values
    • Our History
    • Corporate Responsibility
    • Diversity, Equity, and Inclusion
    • Leadership
    • Citizenship
    • Partnerships
    • Ethics and Compliance
  • Our Science
    • Technologies
    • Pipeline
      • Brentuximab Vedotin
      • Enfortumab Vedotin
      • Ladiratuzumab Vedotin
      • Tisotumab Vedotin
      • Tucatinib
    • Clinical Trials
    • Access to Investigational Therapies
  • Our Medicines
    • ADCETRIS®
      (brentuximab vedotin)
    • PADCEV®
      (enfortumab vedotin-ejfv)
    • TIVDAK®
      (tisotumab vedotin-tftv)
    • TUKYSA®
      (tucatinib)
  • Join Us
    • Benefits
    • Culture
    • Explore Jobs
  • News
  • Investors
  • Search icon Search icon
    Search
Cancel Cancel Search

Event details

Investor Menu
  • Overview
    • Press releases
    • Events and presentations
    • Stock information
      • Stock quote and chart
      • Analyst coverage
    • Financial information
      • Quarterly results
      • SEC filings
      • Annual reports and proxy
    • Corporate governance
      • Corporate governance
      • Executive management
      • Board of directors
      • Committee composition
    • Resources
      • Frequently asked questions
      • Information request
      • Email alerts

First Quarter 2022 Financial Results

April 28, 2022 04:30 PM ET
Add to Calendar
  • Add to Apple Calendar
  • Add to Google Calendar
  • Add to Microsoft Outlook
  • Add to iCalendar
Webcast
Presentation (opens in new window) PDF
You are leaving Seagen

You are now leaving Seagen site. Seagen does not necessarily endorse the organization associated with this link and takes no responsibility for the content contained therein. This resource link is for informational purposes only. Do you want to continue to the external site and leave Seagen.com?

Yes, leave Seagen.com

Investor contact

investors@seagen.com

425-527-4000

Investor email alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Seagen, we will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Seagen to send you the requested Investor Email Alert updates.

* Required

*
*





Email Alert Sign Up Confirmation

  • Patients and Caregivers
  • Diseases We Study
  • Real Stories
  • Clinical Trials
  • Support and Resources
  • Healthcare Professionals
  • Medical Information
  • Clinical Data Requests
  • Investigator-Sponsored Trials
  • Medical Education Grants
  • Site Map
  • Contact Us
  • FAQs
Sign up for updates
Seagen Logo
This website is intended for U.S. residents only.
©2020 Seagen Inc.
  • Privacy Policy
  • Terms and Conditions
  • Social Media Terms
Powered By Q4 Inc. 5.90.0.6 (opens in new window)